175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
Year: 2022
Type: article
Source: Annals of Oncology
Institutions: Champalimaud Foundation, Centro Champalimaud, Harvard University, Massachusetts General Hospital, Institut Curie, Dana-Farber Cancer Institute, Hospital Universitario Virgen del Rocío, Universitair Ziekenhuis Leuven, Samsung Medical Center, Sungkyunkwan University, Tennessee Oncology, Memorial Sloan Kettering Cancer Center, Novartis (United States), Novartis (Switzerland), University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4229067237